Investigational drug · Phase 3
DMB-I
Also called: INN: Latrepirdine, Dimebon
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Alzheimer Type Dementia, Alzheimer Disease, Dementia of Alzheimer Type.
Phase 3Last checked: Nov 19, 2026Latest source record: Dec 10, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
2
Any phase or sponsor naming "DMB-I"
First trial start
2023
Dec 27, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DMB-I", any sponsor or status.
Conditions studied
As listed on its trial records.
- Alzheimer Type Dementia
- Alzheimer Disease
- Dementia of Alzheimer Type
Approved drugs for the same conditions: Alzheimer's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "DMB-I" as an intervention, largest first.
- Efficacy and Safety of DMB-I (INN: Latrepirdine) in Patients With Alzheimer Type DementiaPivotal-lookingRecruiting
Bigespas LTDIndustry
NCT07251023 · 450 participants (planned) · Start Nov 20, 2025 · Primary completion May 2027
Drug: DMB-I (INN: Latrepirdine); Memantine Hydrochloride 20 MG and 1 more · For: Alzheimer Type Dementia
Sites: Kazan', Russia; Moscow, Russia; Nizhny Novgorod, Russia · 12 sites in all
- DMB-I in the Treatment of Alzheimer Type DementiaPivotal-lookingCompleted
Bigespas LTDIndustry
NCT06292351 · 133 participants · Start Dec 27, 2023 · Primary completion Jan 13, 2025
Drug: DMB-I (Dimebon) · For: Alzheimer Disease; Dementia of Alzheimer Type
Sites: Kazan', Russia; Moscow, Russia; Roshchino, Russia · 7 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- QSAR and Free-Wilson Analysis of Bioisosteric Derivatives of Dimebon to Optimize the Search for Potential Inhibitors of Mitochondrial Permeability Transition.
Veselov IM, Zverev DV, Shulga DA, et al. · Molecules 2026
- Efficacy and safety of DMB-I (latrepirdine) therapy in mild to moderate dementia in Alzheimer's disease: results of a multicenter, double-blind, randomized, placebo-controlled, clinical trial in three parallel groups.
Gorin BI, Pozdnyakov SO, Potapova KA, et al. · Sci Rep 2026
- Latrepirdine (Dimebon), a potent 5-HT7 receptor antagonist, modulates stress-mediated behaviors in rodents.
Dhull DK, Seth S, Yocca FD, et al. · Front Pharmacol 2026
- Design, Synthesis, Molecular Docking Study and Biological Evaluation of Novel γ-Carboline Derivatives of Latrepirdine (Dimebon) as Potent Anticancer Agents.
Voggu R, Karmakar A, Puli VS, et al. · Molecules 2023
- Differences in bioavailability and cognitive-enhancing activity exerted by different crystal polymorphs of latrepirdine (Dimebon®).
Gorin BI, Tukhovskaya EA, Ismailova AM, et al. · Front Pharmacol 2023
- Mitochondrial Medicine: A Promising Therapeutic Option Against Various Neurodegenerative Disorders.
Almikhlafi MA, Karami MM, Jana A, et al. · Curr Neuropharmacol 2023
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.